Outlook Therapeutics (OTLK) Current Assets (2015 - 2026)

Outlook Therapeutics (OTLK) has 12 years of Current Assets data on file, last reported at $20.9 million in Q1 2026.

• Current Assets for Q1 2026 came in at $20.9 million, up 17.4% year-over-year; the trailing twelve-month figure through Mar 2026 was $20.9 million (up 17.4% YoY), and the FY2025 annual result was $17.4 million, down 36.57% from the prior year.
• Current Assets grew to $20.9 million in Q1 2026 per OTLK's latest filing, from $17.2 million in the prior quarter.
• Over five years, Current Assets peaked at $66.5 million in Q1 2022 and troughed at $15.7 million in Q4 2024.
• A 5-year average of $34.2 million and a median of $27.5 million in 2022 frame the typical range for Current Assets.
• The sharpest annual moves came in 2022 and 2025: Current Assets jumped 51.96% in 2022, then plunged 69.18% in 2025.
• A 5-year view of Current Assets shows it stood at $61.7 million in 2022, then plunged by 66.94% to $20.4 million in 2023, then declined by 23.16% to $15.7 million in 2024, then grew by 9.57% to $17.2 million in 2025, then gained by 21.78% to $20.9 million in 2026.
• Business Quant data shows OTLK's Current Assets at $20.9 million in Q1 2026, $17.2 million in Q4 2025, and $17.4 million in Q3 2025.